Clinical trial
Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer
NCT00255788 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00255788 |
|---|---|
| Title | Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer |
| Official title | A Randomized Phase II Study of Two Different Schedules of RAD001C in Patients With Recurrent/Metastatic Breast Cancer |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | everolimus |
| Enrollment | 49 |
| Start date | May 10, 2005 |
| Primary completion | Jul 22, 2008 |
| Completion | Jan 18, 2011 |
| First posted | Nov 21, 2005 |
| Last update posted | Aug 4, 2023 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: